3篇
您的检索式：作者名="Hal E.Broxmeyer"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | AMD3100 and CD26 Modulate Mobilization, Engraftment, and Survival of Hematopoietic Stem and Progenitor Cells Mediated by the SDF‐1/CXCL12‐CXCR4 Axis显示文摘 | HAL E.BROXMEYER GIAOHANGOC SCOTTCOOPER TIMOTHYCAMPBELL SHIGEKIITO CHARLIEMANTEL | 2007 | Annals of the New York Academy of Sciences2007，，1： | 1 |
| 2 | Quickly attainable and highly engrafting hematopoietic stem cells显示文摘There are three clinically used sources of hematopoietic stem cells(HSC)and hematopoietic progenitor cells(HPC)for hematopoietic cell transplantation(HCT):bone marrow(BM),umbilical cord blood(CB),and cytokine-induced mobilized peripheral blood(mPB)cells.1–5 Each source of clinically used cells has its advantages and disadvantages.Of these,mPB cells make up the majority of autologous and allogeneic HCT efforts worldwide.The advantage of mPB is that one can,in many cases,usually collect more than enough cells to ensure a rapid and longlasting donor graft,be it for autologous or allogeneic HCT.The“gold”standard for collection of mPB has been,and continues to be,the cells mobilized from the BM to peripheral blood by multiple additions of the cytokine granulocyte colony-stimulating factor(G-CSF)each day over a number of days.However,GCSF-induced mPB does not always yield enough cells for a graft,takes 4–5 days for optimal yield of HSC and HPC,and can entail leukocytapheresis efforts to obtain enough cells for a transplant.This requires the donor to be ready and willing for multiple days of G-CSF treatment.Moreover,there are patients who do not mobilize HSC and HPC well for a number of reasons,including low numbers of these cells inherent in the BM of the patient undergoing an autologous transplant—an example being patients with Fanconi anemia,under such conditions,one might attempt to use gene therapy on the mobilized cells to correct the Fanconi anemia gene defect.New,simple,and less timeconsuming efforts to mobilize HSC and HPC for clinical use would be advantageous.In this context,a recent article by Hoggatt et al.6 describes a new regimen combining two small molecules(GRO-beta and AMD3100)to quickly mobilize HSC and HPC in mice. | Hal E.Broxmeyer | 2019 | Blood Science2019，1，1： | 1 |
| 3 | Enhanced Green Fluorescent Protein Is a Nearly Ideal Long‐Term Expression Tracer for Hematopoietic Stem Cells, Whereas DsRed‐Express Fluorescent Protein Is Not显示文摘 | WenTao Barbara‐GrahamEvans JingYao ScottCooper KennethCornetta Christopher B.Ballas GiaoHangoc Hal E.Broxmeyer | 2009 | STEM CELLS2009，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员